Latest close
$143.63
As of Oct 19, 2026
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Thornburg Investment Management | 4.66% | 3,787,976 | ADDED (+1.6%) |
| Kahn Brothers Group | 4.43% | 218,182 | TRIMMED (-4.0%) |
| DJE Kapital | 3.53% | 1,431,324 | ADDED (+9.6%) |
| Mondrian Investment Partners | 2.92% | 1,473,945 | TRIMMED (-6.8%) |
| Oakmark Funds | 2.06% | 12,073,109 | TRIMMED (-2.4%) |
| OrbiMed Advisors | 1.58% | 663,400 | HELD |
| Atalanta Sosnoff Capital | 1.45% | 642,053 | ADDED (+112.5%) |
| Causeway Capital Management | 1.33% | 954,932 | ADDED (+11.8%) |
| Samlyn Capital | 1.18% | 565,755 | TRIMMED (-22.1%) |
| Sarasin & Partners | 1.11% | 736,662 | TRIMMED (-6.2%) |
| Fairfax Financial Holdings | 0.84% | 172,900 | HELD |
| Semper Augustus | 0.65% | 44,633 | HELD |
| Saturna Capital | 0.31% | 197,643 | ADDED (+25.5%) |
| ACR Alpine Capital Research | 0.08% | 41,146 | ADDED (+4.3%) |
| Mairs & Power Funds | 0.06% | 51,519 | ADDED (+2.3%) |
| Matrix Asset Advisors | 0.02% | 1,671 | HELD |
| Dodge & Cox Funds | 0.01% | 135,750 | TRIMMED (-0.2%) |
| GQG Partners | 0.01% | 53,092 | ADDED (+0.1%) |
| Edgewood Management | 0.01% | 7,718 | HELD |
| Pzena Investment Management | <0.01% | 2,511 | HELD |
| Gardner Russo & Quinn | <0.01% | 1,642 | TRIMMED (-23.3%) |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
| Institutions holding | 3,793 of 8,857 filers |
| Long-only filers among them | 3,779 |
| Change vs 2026 Q1 | +87 net · 2,118 entered · 2,031 exited |
| Shares reported, all filers | 1,958,782,160 |
| Reported value, all filers | $248.9B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $65.0B |
| Net income · FY2025 | $18.3B |
| Total assets · FY2025 | $136.9B |
| Shares outstanding | 2,467,171,638 |
| Market cap (at latest close) | $354.4B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 7, 2026. Shares outstanding as reported Jul 31, 2026.
| Shares short · Sep 15, 2026 | 34,430,712 |
| Share of shares outstanding | 1.40% |
| Days to cover | 4.23 |
Shares short at recent settlements — Jun 30, 2026: 31.4M · Jul 15, 2026: 29.4M · Jul 31, 2026: 28.3M · Aug 14, 2026: 24.5M · Aug 31, 2026: 30.3M · Sep 15, 2026: 34.4M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.
| Shares failed to deliver · Sep 15, 2026 | 6,473 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Sep 15, 2026 | <0.1% |
Fails to deliver at recent settlements — Jun 30, 2026: 2K · Jul 15, 2026: 0 · Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 2K · Sep 15, 2026: 6K.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 17 sales by 5 insiders ($30.0M).
Source: SEC Form 4 filings, as of Oct 20, 2026. Open-market transactions only.
1 member of Congress reported buying (1 purchase vs 0 sales). Bought by Republicans. Latest buy: Aug 19, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Oct 3, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Growth — Revenue up every year for 5 straight years
· Graham — Sound finances and a long run of profits
· Lynch PEG — Cheap against its growth rate
· Dividend Growth — Dividends raised for more than 10 years
· Neff Total Return Ratio — Growth plus dividends divided by P/E is high
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
· Shareholder Yield — Cash returned through dividends and buybacks
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Key figures
· Growth — Latest revenue: $65.0B · 5-yr revenue CAGR: 9.4% · Straight growth years: 6
· Graham — Current ratio: 1.54 · Straight profitable years: 19 · Debt ratio: — · Latest net income: $18.3B
· Lynch PEG — P/E: 19.61 · 5-yr EPS growth: 21.2% · PEG: 0.92
· Dividend Growth — Dividend per share: 3.28 · Dividend yield: 2.3% · Straight dividend years: 19 · 10-yr dividend growth: 77.3%
· Neff Total Return Ratio — EPS growth: 21.2% · Dividend yield: 2.3% · P/E: 19.61 · Neff ratio: 1.20
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 12.60 · Operating cash flow: $16.5B · Net income: $18.3B
· Shareholder Yield — Shareholder yield: 3.7% · of which dividends: 2.3% · of which buybacks: 1.4%
· Bought by Members — Members buying: 1 · Buy txns: 1 · Sell txns: 0 · Latest buy: Aug 19, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 10 of the last 20 quarterly lists; latest 2026 Q1, ranked #48 of 50.
· Politician BEST — appeared in 11 of the last 20 quarterly lists; latest 2025 Q3, ranked #45 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 10 | 50.0% | +4.8% | +2.1% | +2.7% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold MRK: MICROSOFT CORP (MSFT) · Apple Inc. (AAPL) · JPMORGAN CHASE & CO (JPM) · ExxonMobil Holdings Corp (XOM) · AMAZON COM INC (AMZN) · Meta Platforms, Inc. (META) · Alphabet Inc. (GOOG) · NVIDIA CORP (NVDA) · Alphabet Inc. (GOOGL) · TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM).
Filings audit: every filing lens on Merck & Co., Inc. (MRK), scored — GetCoattail Research.
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.